Company Overview - Avalo Therapeutics, Inc. is a clinical stage biotechnology company focused on the treatment of immune dysregulation [3] - The company's lead asset is AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases [3] - Avalo has two additional drug candidates: quisovalimab (anti-LIGHT monoclonal antibody) and AVTX-008 (BTLA agonist fusion protein) [3] Product Details - AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity [4] - IL-1β is a central driver in the inflammatory process, and its overproduction is implicated in many autoimmune and inflammatory diseases [4] - Evidence suggests that inhibition of IL-1β could be effective in treating hidradenitis suppurativa and various inflammatory diseases in dermatology, gastroenterology, and rheumatology [4] Upcoming Events - Garry A. Neil, M.D., CEO and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 10:00 a.m. ET [1] - A live webcast and replay of the presentation will be available on the Avalo Therapeutics website for at least 30 days [2]
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference